An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A company called Vivani is working on a small implant that would slowly release semaglutide, the drug you’ve probably heard as Ozempic or Wegovy, so people wouldn’t have to give themselves weekly injections. The idea is to make it easier for people to stick with a GLP‑1 weight-loss treatment over the long run by turning it into a long‑acting implant instead of a shot or pill. Semaglutide is a lab-made version of a natural hormone your gut makes after you eat. That hormone helps regulate appetite and how fast your stomach empties. In drug form it makes many people feel less hungry and helps them lose weight; it’s the active ingredient in brand-name drugs used for diabetes and for chronic weight management. GLP‑1 is the class of drugs that semaglutide belongs to; when people say “GLP‑1 drugs,” they mean medicines that mimic that gut hormone’s effects. The snippet says Vivani is developing an implant to deliver semaglutide, but it doesn’t describe any study results or human trials. So we don’t yet know whether the implant works the same as injections, how long one implant would last, or whether it’s been tested in people. What the announcement implies is more about convenience and adherence (how consistently people keep taking a medicine) than about new clinical proof. Until company data or independent trials are published, we can’t say how effective or safe the implanted version will be compared with current weekly shots. This matters because one common problem with weight-loss drugs is people stopping them over time, either because injections are inconvenient or they don’t like the routine. A long‑acting implant that reliably delivers the drug could help people keep getting the medication without thinking about it every week. That could improve outcomes for people already prescribed semaglutide for weight loss or diabetes, if the implant proves safe and effective. At the same time, there are important caveats. An implant carries different risks than an injection: it requires a minor procedure to put in and remove it, and could cause local infections, pain, or device failures. We also don’t know regulatory status from the snippet—whether any health authority has reviewed or approved this device—or long‑term safety data. People who are pregnant, planning pregnancy, or who have certain health conditions should always check with their doctor before switching medications or delivery methods. Bottom line: Vivani says it’s making a semaglutide implant to make long‑term use easier, but until trial results and safety data are released, it’s a promising idea rather than a proven new option.
Source: Pluang